Business Insider

SAGE Therapeutics: Hold Rating Following SAGE-324 Clinical Trial Setback

Needham analyst Ami Fadia has maintained their neutral stance on SAGE stock, giving a Hold rating on July 18. Ami Fadia has given his Hold rating due to a combination of factors related to SAGE ...
Business Insider

SAGE Therapeutics’ Neutral Rating and Price Target Adjustment Following KINETIC-2 Trial Setbacks

Mizuho Securities analyst Uy Ear has maintained their neutral stance on SAGE stock, giving a Hold rating yesterday. Uy Ear’s rating is based on a combination of factors including the disappointing ...
Insider Monkey

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands ...
Reuters

Biogen and Sage to scrap neurological disorder drug development after trial failure

July 24 (Reuters) - Biogen (BIIB.O), opens new tab and Sage Therapeutics (SAGE.O), opens new tab do not plan to conduct further studies for their neurological disorder drug after it failed in a ...
Seeking Alpha

Sage slips as Huntington’s Disease therapy fails in mid-stage trial

Shares of Sage Therapeutics (NASDAQ:SAGE) fell in the premarket on Wednesday after the company said dalzanemdor, its candidate for an inherited neurological condition called Huntington’s Disease, ...
Seeking Alpha

Biogen, Sage discontinue neuro candidate after mid-stage setback

Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) announced Wednesday that they will no longer advance their oral experimental therapy SAGE-324 for essential tremor following a failure in a mid ...